The activation of glycogen synthase kinase 3β (GSK‐3β) and the deterioration of spatial memory represent prominent pathological and clinical manifestations of Alzheimer's disease (AD). This evidence concerns the gene GSK3B and early-onset autosomal dominant Alzheimer disease.